The levels of serum vascular endothelial growth factor and Bcl-2 and association between them in stage IV non-small cell lung cancer

Year 2007, Volume: 22 Issue: 2, 76 - 81, 01.03.2007

Esra Ertan Yazar Hilal Oğuz Soydinç Aziz Yazar Akif Özgül Faruk Taş Vildan Yasasever Hakan Çamlıca Veysel Yılmaz

Abstract

OBJECTIVES In most of the tumors, vascular endothelial growth fact o r (VEGF) shows its ang io g enic effects by increasing the level of the Bcl-2 onc o protein. The aim of this study was to inv e st ig ate the serum levels of VEGF and Bcl-2 and the possible association betw een them in stage III and stage IV non-small cell lung cancer (NSCLC). METHODS Twenty eight patients in stage III, 24 patients in stage IV and 25 healthy subjects were enrolled in the study. Serum Bcl-2 and VEGF levels were analyzed by ELISA. RESULTS The VEGF (pg/ml) level in stage IV (11 6.7± 151.7) and stage III ( 11 6.2 ± 1 4 0.6) patients was higher than healthy subjects ( 34.5 ± 6.3) (p

Keywords

Carcinoma, Non-Small-Cell Lung, Vascular Endothelial Growth Factor A, Proto-Oncogene Proteins c-bcl-2, Neoplasm Staging

Evre IV küçük hücreli dışı akciğer kanserinde serum vasküler endotelyal büyüme faktörü ve Bcl-2 düzeyleri ve aralarındaki ilişki

Abstract

AMAÇ Tümörlerin çoğunda vasküler endotelyal büyüme faktör (VEBF) angiogenik etkisini Bcl-2 onkoproteinini artırarak göstermektedir. Bu çalışmadaki amacımız evre III ve evre IV hücreli dışı akc iğer kans eri'nde (KHDAK) VEBF ve Bcl-2 düzeylerini ve aralarındaki olası ilişkiyi araştırmaktır. GEREÇ VE YÖNTEM Çalışmaya 28 evre III ve 24 evre IV KHDAK'li hasta ile kontrol grubuna sağlıklı 25 kişi alındı. ELISA yöntemi ile serum VEBF ve Bcl-2 düzeyleri çalışıldı. BULGULAR VEBF (pg/ml) düzeyi evre IV (116.7±151.7) ile evre III (116.2±140.6) hastalarda kontrollere (34.5±6.3) göre oldukça yüksek bulundu (p < 0.0001). Evre IV ile evre III arasında VEBF açısından bir farklılık saptanmadı. Üç grupta ölçülen
Bcl-2 düzeyi farklı değildi (p=0.15). Grupların hiçbirinde VEBF ile Bcl-2 arasında anlamlı bir ilişki saptanmadı (p=0.109). SONUÇ Evre IV KHDAK’li hastalarda VEBF düzeyi evre III hastalardan
daha yüksek değildi. Evre IV KHDAK’li hastalarda VEBF ile Bcl-2 arasında olası ilişkiyi ortaya çıkarmak için daha fazla angiogenik, antiapoptotik sitokin ve daha fazla hasta ile yapılan çalışmalara ihtiyaç olduğu düşüncesindeyiz.

Keywords

Küçük hücreli dışı akciğer kanseri, vasküler endotelyal büyüme faktörü, Bcl-2.

References

• 1. Ohta M, Tsuchiya R, Shimoyama M, Sawamura K, Mori T, Miyazawa N, et al. Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer. Results of a randomized prospective study. The Japan Clinical Oncology Group. J Thorac Cardiovasc Surg 1993;106(4):703-8.
• 2. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267(5203):1456-62.
• 3. Kondo S, Yin D, Aoki T, Takahashi JA, Morimura T, Takeuchi J. bcl-2 gene prevents apoptosis of basic fibroblast growth factor-deprived murine aortic endothelial cells. Exp Cell Res 1994;213(2):428-32.
• 4. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst
• 5. Yano S, Nishioka Y, Goto H, Sone S. Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules. Cancer Sci 2003;94(6):479-85.
• 6. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 1992;340(8812):145-6.
• 7. Dias S, Shmelkov SV, Lam G, Rafii S. VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 2002;99(7):2532-40.
• 8. Beierle EA, Strande LF, Chen MK. VEGF upregulates Bcl-2 expression and is associated with decreased apoptosis in neuroblastoma cells. J Pediatr Surg 2002;37(3):467-71.
• 9. Nör JE, Christensen J, Liu J, Peters M, Mooney DJ, Strieter RM, et al. Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 2001;61(5):2183-8.
• 10. Huang CI, Neuberg D, Johnson BE, Wei JY, Christiani DC. Expression of bcl-2 protein is associated with shorter survival in nonsmall cell lung carcinoma. Cancer 2003;98(1):135-43.
• 11. Higashiyama M, Doi O, Kodama K, Yokouchi H, Nakamori S, Tateishi R. bcl-2 oncoprotein in surgically resected non-small cell lung cancer: possibly favorable prognostic factor in association with low incidence of distant metastasis. J Surg Oncol 1997;64(1):48-54.
• 12. Koukourakis MI, Giatromanolaki A, O'Byrne KJ, Cox J, Krammer B, Gatter KC, et al. bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer. Clin Exp Metastasis 1999;17:545-54.
• 13. Giatromanolaki A, Koukourakis MI, Kakolyris S, Turley H, O'Byrne K, Scott PA, et al. Va s c u l a r endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 1998;4(12):3017-24.
• 14. Gridelli C, Rossi A, Maione P. New antiangiogenetic agents and non-small cell lung cancer. Crit Rev Oncol Hematol 2006;60(1):76-86.
• 15. Masuya D, Huang C, Liu D, Kameyama K, Hayashi E, Yamauchi A, et al. The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients. Cancer 2001;92(10):2628-38.
• 16. Toomey D, Smyth G, Condron C, Kay E, Conroy R, Foley D, et al. Immune function, telomerase, and angiogenesis in patients with primary, operable nonsmall cell lung carcinoma: tumor size and lymph node status remain the most important prognostic features. Cancer 2001;92(10):2648-57.
• 17. Fontanini G, Lucchi M, Vignati S, Mussi A, Ciardiello F, De Laurentiis M, et al. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997;89(12):881-6.
• 18. Kojima H, Shijubo N, Abe S. Thymidine phosphorylase and vascular endothelial growth factor in patients with Stage I lung adenocarcinoma. Cancer 2002;94(4):1083-93.
• 19. Ludovini V, Gregorc V, Pistola L, Mihaylova Z, Floriani I, Darwish S, et al. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer. Lung Cancer 2004t;46(1):77-85.
• 20. Tamura M, Ohta Y. Serum vascular endothelial growth f a c t o r-C level in patients with primary nonsmall cell lung carcinoma: a possible diagnostic tool for lymph node metastasis. Cancer 2003;98(6):1217-22.
• 21. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2(10):795-803.
• 22. Pidgeon GP, Barr MP, Harmey JH, Foley DA, Bouchier-Hayes DJ. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer 2001;85(2):273-8.
• 23. Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol 2000;157(6):1893-903